Abstract 1067
Background
To report on the local response (LR), biochemical progression-free (bPFS) and distant-progression free (DPFS) survival after stereotactic body radiotherapy (SBRT) for bone and lymph node prostate cancer oligometastases.
Methods
Within the context of a prospective SBRT trial for oligometastases (NCT03486431), 54 bone and lymph node oligometastases, all detected on PSMA-PET/CT, were irradiated in 40 prostate cancer patients between July 2017 and December 2018. Of these patients, 35 had hormone-sensitive and 5 had castration-resistant disease. Short-term concomitant ADT was recommended in all hormone-naïve patients but decided in consultation with the patient. Ultimately, 20 patients received ADT while 20 did not. The two groups were well balanced, with no significant differences in age, Gleason score, PSA, lesion type, number or timing of metastases, and fractionation schedule. All patients received a PSMA-PET/CT at 6 months after SBRT. PSMA-RADS v1.0 was used to categorize the response of the treated lesion. Quality-of-life (QOL) scoring was performed using the EORTC QLQ-C30 questionnaire at baseline, 3 and 6 months.
Results
Median follow-up for all patients was 9.6 months (IQR 6.3 – 12.9 months). Up till now, 42 lesions could be reevaluated at 6 months after SBRT with PSMA-PET/CT, of which 30 showed complete response, 8 partial response and 4 stable disease. No symptomatic or local progression was observed in the irradiated lesions. There was no statistically significant influence of ADT, fractionation, type of lesion or lesion size on LR. Patients who received ADT had significantly improved bPFS (median bPFS of 6.9 months versus median not reached; p = 0.0017) and DPFS (median DPFS of 6.8 months versus 17.3 months; p = 0.0021). We did not observe any clinically relevant changes in QOL scores between the patients who received ADT versus those who refused. Overall, QOL scores remained stable for both groups at baseline, 3 and 6 months.
Conclusions
These prospective data, although non-randomized, suggest that oligometastatic prostate cancer patients treated with SBRT could potentially benefit from short-term ADT. Longer follow-up will determine if ADT simply delays progression or truly alters the course of the disease.
Clinical trial identification
NCT03486431.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract
1707 - Clinical utility of precision immunoprofiling and monitoring of the tumor microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: results from a phase II study for biomarker analysis (EPOC1702)
Presenter: Keisuke Kirita
Session: Poster Display session 3
Resources:
Abstract
3594 - Tumor mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
744 - The decrease of TMB, TNB and HLA expression are the Mechanism of Drug Resistance of NSCLC to immunosuppressive PD-1/PD-l1.
Presenter: Sheng Yu
Session: Poster Display session 3
Resources:
Abstract
2350 - Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Presenter: Rika Kizawa
Session: Poster Display session 3
Resources:
Abstract
5930 - A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors.
Presenter: Javier Pérez-peña
Session: Poster Display session 3
Resources:
Abstract
6127 - Alterations of TMB and TCR repertoires during Chemotherapy in East Asian lung cancer patients without TKI-related driver gene mutations
Presenter: Lele Song
Session: Poster Display session 3
Resources:
Abstract
1310 - Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody.
Presenter: Motoo Nomura
Session: Poster Display session 3
Resources:
Abstract
2286 - Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment
Presenter: Nicholas Willumsen
Session: Poster Display session 3
Resources:
Abstract
4107 - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy
Presenter: Julie Stein
Session: Poster Display session 3
Resources:
Abstract